Literature DB >> 33719816

Individual, social and structural factors influencing PrEP uptake among cisgender women: a theory-informed elicitation study.

Anne M Teitelman1, Hong-Van Tieu2, Dalmacio Flores1, Jacqueline Bannon3, Bridgette M Brawner1, Annet Davis1, Paige Gugerty1, Beryl Koblin1,4.   

Abstract

The underutilization of pre-exposure prophylaxis (PrEP) among cisgender women in the U.S. limits this population's ability to reduce their risk for HIV infection, especially within the unique individual, social and structural systems they navigate. There is a need to identify the relevant multi-level barriers and facilitators to PrEP use among cisgender women to inform theory-guided efforts that address HIV disparities by race/ethnicity among cisgender women. Guided by the Integrated Behavioral Model and the Behavioral Model of Vulnerble Populations we conducted 41 interviews with PrEP eligible cisgender women in New York City and Philadelphia. Directed content analysis identified 11 modal behavioral beliefs crucial to PrEP uptake, including anticipated negative social consequences, 5 normative beliefs centered on available social supports, and 9 control beliefs such as anticipated barriers such as cost. Awareness and knowledge of PrEP as a biobehavioral HIV prevention method is limited for this sample. Through conventional content analysis we identified interpersonal and structural barriers to PrEP uptake including lack of partner support, transportation, mental health challenges, and challenges in accessing PrEP care. Potential solutions to structural barriers were enumerated along with implications for future intervention work and public health programming.

Entities:  

Keywords:  HIV prevention; PrEP; cisgender women; qualitative research; risk reduction

Mesh:

Year:  2021        PMID: 33719816      PMCID: PMC8426410          DOI: 10.1080/09540121.2021.1894319

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  33 in total

1.  The Behavioral Model for Vulnerable Populations: application to medical care use and outcomes for homeless people.

Authors:  L Gelberg; R M Andersen; B D Leake
Journal:  Health Serv Res       Date:  2000-02       Impact factor: 3.402

2.  Three approaches to qualitative content analysis.

Authors:  Hsiu-Fang Hsieh; Sarah E Shannon
Journal:  Qual Health Res       Date:  2005-11

3.  Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.

Authors:  Pamela M Murnane; Connie Celum; Nelly Mugo; James D Campbell; Deborah Donnell; Elizabeth Bukusi; Andrew Mujugira; Jordan Tappero; Erin M Kahle; Katherine K Thomas; Jared M Baeten
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

4.  Enhancing adoption of evidence-based HIV interventions: promotion of a suite of HIV prevention interventions for African American women.

Authors:  Gina M Wingood; Ralph J DiClemente
Journal:  AIDS Educ Prev       Date:  2006-08

5.  Brief Report: PrEP Eligibility Among At-Risk Women in the Southern United States: Associated Factors, Awareness, and Acceptability.

Authors:  Anar S Patel; Lakshmi Goparaju; Jessica M Sales; Cyra Christina Mehta; Oni J Blackstock; Dominika Seidman; Igho Ofotokun; Mirjam-Colette Kempf; Margaret A Fischl; Elizabeth T Golub; Adaora A Adimora; Audrey L French; Jack DeHovitz; Gina Wingood; Seble Kassaye; Anandi N Sheth
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-15       Impact factor: 3.731

6.  Intimate Partner Violence, HIV Pre-Exposure Prophylaxis (PrEP) Acceptability, and Attitudes About Use: Perspectives of Women Seeking Care at a Family Planning Clinic.

Authors:  Teagen L O'Malley; James E Egan; Mary E Hawk; Sarah E Krier; Jessica G Burke
Journal:  AIDS Behav       Date:  2021-02

7.  PrEP Stigma, HIV Stigma, and Intention to Use PrEP among Women in New York City and Philadelphia.

Authors:  Deepti Chittamuru; Victoria Frye; Beryl A Koblin; Bridgette Brawner; Hong-Van Tieu; Annet Davis; Anne Teitelman
Journal:  Stigma Health       Date:  2019-10-31

8.  Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention.

Authors:  Suzan M Walters; Kathleen H Reilly; Alan Neaigus; Sarah Braunstein
Journal:  Harm Reduct J       Date:  2017-06-29

9.  Integrating HIV Preexposure Prophylaxis With Community-Based Syringe Services for Women Who Inject Drugs: Results From the Project SHE Demonstration Study.

Authors:  Alexis M Roth; Nguyen K Tran; Marisa Felsher; Annette B Gadegbeku; Brogan Piecara; Rachel Fox; Douglas S Krakower; Scarlett L Bellamy; K Rivet Amico; Jose A Benitez; Barbara Van Der Pol
Journal:  J Acquir Immune Defic Syndr       Date:  2021-03-01       Impact factor: 3.771

10.  Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women.

Authors:  Lakshmi Goparaju; Nathan C Praschan; Lari Warren-Jeanpiere; Laure S Experton; Mary A Young; Seble Kassaye
Journal:  J AIDS Clin Res       Date:  2017-09-25
View more
  3 in total

1.  Examining HIV Diagnosis and Linkage to PrEP Prescription Among Members at An Integrated Health System in the Southeast United States.

Authors:  Teaniese L Davis; Mona Mittal; Adanna C Oragwu; Min Qi Wang; Bradley O Boekeloo
Journal:  AIDS Behav       Date:  2022-09-12

2.  Factors Associated with Intention to Initiate Pre-exposure Prophylaxis in Cisgender Women at High Behavioral Risk for HIV in Washington, D.C.

Authors:  Rachel K Scott; Shawnika J Hull; Jim C Huang; Megan Coleman; Peggy Ye; Pam Lotke; Jason Beverley; Patricia Moriarty; Dhikshitha Balaji; Allison Ward; Jennifer Holiday; Ashley R Brant; Martha Cameron; Rick Elion; Adam Visconti
Journal:  Arch Sex Behav       Date:  2022-05-27

3.  Pre-exposure Prophylaxis (PrEP) Initiation Among Black and Latina Cisgender Women Receiving HIV Prevention Care Coordination Services in New York City.

Authors:  Jelani B Cheek; Matthew B Feldman; Noelisa Montero; Gina F Gambone; Susie Hoffman; Oni J Blackstock
Journal:  AIDS Behav       Date:  2022-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.